Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer

Sadat City University

Overview

chlorpromazine displays a series of remarkable bio-molecular effects in cancer cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide 3-kinase/mammilian target of rapamycin (PI3K/mTOR) axis, induction of cytotoxic autophagy, inhibition of glutamate and DRD2 receptors. This study will evaluate the addition of chlorpromazine to the first-line therapeutic protocol in colon cancer stage III.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Colon Cancer Stage III

Interventions

ChlorproMAZINE 50 MGDRUG

The experimentall group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours) plus choloropromazine 50 mg daily for 6 months

ControlDRUG

The control group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients age ≥18 years old. * Patients with histologically confirmed surgically resected stage III colon cancer * No rectal cancer * Stage III disease (any pT, N1-2, M0) * Patients should have a good performance status according to Eastern Cooperative Oncology Group (ECOG) score (ECOG 0-2). * Patients with normal organic function as defined for the following criteria: * Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 times the upper normal limit of the local laboratory (LSN-LL); * Total serum bilirubin ≤ 2.0 x ULN-LL; * Absolute neutrophil count ≥ 1,500 / mm3; * Platelet count ≥ 100,000 / mm3; * Hemoglobin ≥ 8.0 g / dl; * Serum creatinine ≤ 1.5 x ULN-LL * Patients should undergone curative-intent complete surgical resection * Patients have at least one month from any major surgery to start of intervention * Written informed consent before enrollment Exclusion Criteria: * Patients with concurrent other malignancy or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer or in-situ cervical cancer) * Patients with metastatic disease * Patients who scheduled to receive any form of further adjuvant cancer therapy (A malignancy currently under active therapy * Pregnant or breast-feeding patients * Patients with known hypersensitivity or intolerance to CPZ * Patients with serious illness or psychiatric condition. * Patients have current participation in other protocols with experimental drugs. * Patients with no ability to ingest food orally. * Patients who have familial adenomatous polyposis, hereditary non-polyposis rectal cancer, or inflammatory bowel disease * Patients who are taken other chemoprevention drugs (ex. NSAIDs, Aspirin)

Locations (1)

Faculty of Pharmacy, University of Sadat city

Madīnat as Sādāt, Menoufia, Egypt

Outcomes

Primary Outcomes

Disease-free survival

Disease-free survival as measured by Logrank

Time frame: one year

Secondary Outcomes

Overall survival

Overall survival as measured by Logrank

Time frame: one year

Time occurrence of new primary colon cancer and new polyps

Time occurrence of new primary colon cancer and new polyps as measured by Logrank

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.